A popular anti-aging drug combination causes brain damage in mice
Millions of people are already experimenting with senolytic treatments to slow aging. A new study now shows that one of the most popular combinations causes brain damage strikingly similar to multiple sclerosis…
Dasatinib and quercetin — known in longevity circles as D+Q — has been one of the most talked-about senolytic combinations for years. Quercetin is sold freely as a dietary supplement; dasatinib is a cancer drug that some longevity enthusiasts use off-label. Early animal studies and small human trials generated real excitement. But a new study introduces a serious complication.
Researchers found that D+Q damages a specific type of stem cell in the brain: oligodendrocyte precursor cells. These cells are responsible for maintaining and repairing myelin — the protective sheath that wraps around nerve fibers and allows electrical signals to travel efficiently, much like insulation around a wire. When myelin breaks down, neurological function deteriorates. That is precisely the mechanism underlying multiple sclerosis, where the immune system attacks the myelin sheath. The damage observed in mouse brains after D+Q treatment closely resembled what is seen in MS patients.
The logic of senolytics is sound — but the targeting is imprecise
The biological reasoning behind senolytics is well-established. As we age, so-called senescent cells accumulate throughout the body. These cells stop dividing but refuse to die, and they secrete inflammatory molecules that damage surrounding healthy tissue. Senolytics are designed to selectively clear these dysfunctional cells. In animal models, the results have been impressive: improved muscle function, extended lifespan, reduced age-related disease.
The problem is specificity. A drug that kills senescent cells can inadvertently hit other cells that happen to share the same molecular markers. Oligodendrocyte precursor cells in the brain appear to be one such unintended target. They display characteristics that D+Q acts upon — leading to damage rather than the intended selective clearance of aged cells.
A warning for the self-experimentation community
This study was conducted in mice, not humans — a critical caveat. Mouse brains do not always respond identically to human brains, and the dosages and delivery methods used in animal studies often differ significantly from what people self-administer. But the finding is serious enough to warrant attention, particularly because D+Q is already widely used outside of controlled clinical settings, without medical supervision.
The researchers are not calling for an end to senolytic research. Rather, they are urging far greater scrutiny of potential neurological side effects. The longevity community has a tendency to rapidly translate promising results into personal practice. This study is a reminder that the road from mouse to human is long — and that the brain is an especially vulnerable organ to experiment on without complete information. What remains unanswered is what happens in people who have been taking D+Q for years.